Benitec Biopharma Ltd.

01/04/2018 | Press release | Distributed by Public on 01/03/2018 15:57



Benitec Biopharma to Present at Biotech Showcase™ 2018 in San Francisco

Sydney Australia, 4 January 2018: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that Dr David Suhy, Chief Scientific Officer, will present at the 10th Annual Biotech Showcase™ in San Francisco, CA during the J.P. Morgan Healthcare Conference. Details of the presentation are as follows:

Date: Monday 8 January 2018

Time: 10:30am

Location: Hilton Union Square in Yosemite C (Ballroom Level)

The presentation will provide highlights on recent advancements in the Company's pipeline programs including progression of both its head and neck squamous cell carcinoma program (BB-401) and its oculopharyngeal muscular dystrophy program (BB-301) towards the clinic, as well as the outlook for 2018.

Greg West, Chief Executive Officer, stated, "We are delighted to again be presenting at the Annual Biotech Showcase which takes place during one of the largest Healthcare Conferences in the world, providing excellent opportunities for showcasing the Benitec pipeline programs. We look forward to sharing our recent milestones and outlook during the conference, as we progress towards returning to a clinical stage company in 2018."

A copy of the presentation will be posted to the Company's website.

Management will be available for one-on-one meetings through the conference. Should you have interest in meeting with the Company at the conference, please contact a member of the Benitec investor relations team below.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website

Australia Investor Relations

United States Investor Relations

Market Eye

M Group Strategic Communications

Orla Keegan

Jay Morakis


Managing Director

Tel: +61 (2) 8097 1201

Tel: +1 212.266.0190

Email:[email protected]

Email:[email protected]

About Benitec Biopharma Limited:

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including OPMD, head & neck squamous cell carcinoma, retinal based diseases such as wet age-related macular degeneration, and hepatitis B. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain, cancer immunotherapy and retinitis pigmentosa.

About Biotech Showcase™:

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

Now in its tenth year, Biotech Showcase™ 2018 is expected to attract upwards of 3,000 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies. The event is being held January 8-10, 2018 at the Hilton San Francisco Union Square.

Safe Harbor Statement:

This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in this ASX/Nasdaq announcement are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialise its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.